Translating Bold Science into Patient Impact
The foundational science behind OLIG2 inhibition, the role of cancer stem cells, and the dual-action mechanism of CT-179 has been rigorously validated in leading scientific literature.
Clinical trials are the vital bridge between groundbreaking laboratory science and new standards of care. Curtana is deeply committed to rigorous clinical execution, patient safety, and transparent collaboration with leading global neuro-oncology networks.
Clinical trials are the vital bridge between groundbreaking laboratory science and new standards of care. Curtana is deeply committed to rigorous clinical execution, patient safety, and transparent collaboration with leading global neuro-oncology networks.
Advancing the OPAL Trial
Curtana is conducting our first-in-human Phase 1 clinical trial, the OPAL Trial, at six leading neuro-oncology centers of excellence in Australia. This study is being executed in close collaboration with the Australian Brain Cancer Research Alliance (ABCARA) and the Cooperative Trials Group for Neuro-Oncology (COGNO).
Objectives
The primary goal of the Phase 1 OPAL trial is to rigorously evaluate the safety, tolerability, pharmacokinetics, and optimal dosing of oral CT-179.
Current Status & Focus
The initial phase of the trial will enroll adult patients with Recurrent Glioblastoma (rGBM), with the first patient expected to be dosed in Q2 2026.
Future Expansion
Following the initial safety and tolerability evaluation of CT-179 in patients with rGBM, the trial will evaluate CT-179 in combination with standard radiation therapy in adults with Newly Diagnosed MGMT-unmethylated GBM, with the first patient targeted for Q3 2027.
Expanded Access Policy
